Travere Therapeutics, Inc.
https://travere.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Travere Therapeutics, Inc.
Alnylam/Regeneron Face Crowded IgA Nephropathy Field, But Combinations Likely
Phase II data position cemdisiran well for Phase III, but several agents are already well ahead. However, Alnylam foresees a polypharmacy approach.
Deal Watch: Ovid Teams With Gensaic On Phage-Derived, Gene-Delivered Therapies
Plus deals involving Glaukos/iVeena, Daré/Hennepin Life Sciences, Prevail/Lacerta, Chugai/Noile-Immune, Horizon/Q32, EpiAxis/Peptilogics and more.
COVID-19 Vaccine Skycovion Among Raft Of New EU Filings
EU marketing authorization applications for 12 products, including Skycovion, trastuzumab duocarmazine, alpelisib and sparsenta, are now being evaluated by the European Medicines Agency.
Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field
Roche is not disclosing Phase II results yet, but must exceed late-stage rival drug’s 50% reduction in protein build up to compete in immunoglobulin A nephropathy.
Company Information
- Industry
-
Pharmaceuticals
-
Drug Delivery
- Nasal
-
Drug Delivery
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Desert Gateway, Inc.
- Kyalin Biosciences, Inc.
- Manchester Pharmaceuticals LLC.
- Orphan Technologies Ltd.
- Retrophin, Inc.